Zeneca Accolate reduces direct asthma costs by $9.50 per patient per month, pharmacoeconomic study claims.

ZENECA ACCOLATE PHARMACOECONOMIC TRIAL CLAIMS $9.50 REDUCTION in direct asthma costs per patient per month. Preliminary results from a McGill University pharmacoeconomic study of 146 mild to moderate asthma patients was presented at the American Thoracic Society meeting in Seattle May 23. The study found that treatment with the oral leukotriene antagonist Accolate (zafirlukast) produced $9.50 per patient per month in savings from physician visits, hospital visits, adverse events and medications. The price of Accolate was not considered in the analysis.